陈天桥：互联网套路要投出Neuralink很难，鼓励中国企业直接竞争

Core Insights - The development of hard technology innovations, such as brain-computer interfaces (BCIs), requires patient capital that is willing to support long-term research and commercialization efforts, rather than expecting quick returns typical of the internet industry [1][3] - Notable investor Chen Tianqiao emphasizes that the BCI sector in China has seen significant investment growth and impactful results over the past four years, with Shanghai emerging as a global technology hub for BCIs [1][3] Investment Landscape - Shanghai-based JieTi Medical announced a B-round financing of 350 million yuan, which enabled the initiation of China's first invasive BCI clinical trial [3] - Another company, QiangNai Technology from Hangzhou, has raised over 200 million USD, significantly boosting the valuations of BCI firms [3] Investment Philosophy - Chen Tianqiao warns against treating BCIs merely as a profit-making opportunity, stressing that the hard technology sector cannot be evaluated using the short-cycle, quick-return models of the internet industry [3][4] - He argues that the BCI field requires long-term, stable support to navigate the lengthy processes of technology validation and market cultivation [3][4] Company Development - Brain Tiger Technology, founded with the goal of becoming China's equivalent to Neuralink, faces challenges due to the long development timelines, which can extend beyond 10 years [4] - The founder, Tao Hu, has transitioned from a prestigious academic career to fully commit to the startup, highlighting the dedication required for scientific entrepreneurship [4] Technological Advancements - Brain Tiger Technology has achieved breakthroughs in real-time language decoding and motor decoding, gaining attention from top scientific journals [4] - Chen Tianqiao emphasizes the need for a robust innovation ecosystem and technical platform to support scientific entrepreneurship, advocating for competition with established players like Neuralink [4]